Table 3.
Associations between S100A8 expression and clinical pathological characteristics Sensitivity analysis.
| Clinicopathological characteristics | No. of studies | No. of patients | Risk of high S100A8 OR (95% CI) | Significant Z | P-value | Heterogeneity I2 (%) | P-value | Model | |
|---|---|---|---|---|---|---|---|---|---|
| Gender (male vs female) | 4 | 339 | 1.93 (0.76–4.89) | 1.39 | 0.164 | 65.0 | 0.036 | Random effect | |
| Tumor differentiation (poor vs moderate/well) | 5 | 439 | 3.91 (1.48–10.27) | 2.76 | 0.006 | 73.4 | 0.005 | Random effect | |
| TNM stage (III–IV vs I–II) | 4 | 402 | 1.34 (0.51–3.51) | 0.59 | 0.554 | 69.2 | 0.021 | Random effect | |
| Lymphatic metastasis (N1/N2/N3 vs N0) | 5 | 448 | 1.80 (1.17–2.77) | 2.68 | 0.007 | 0.0 | 0.445 | Fixed effect | |
| ER (positive vs negative) | 3 | 319 | 0.31 (0.21–0.47) | 5.71 | 0.000 | 0.0 | 0.443 | Fixed effect | |
| PR (positive vs negative) | 3 | 319 | 0.29 (0.13–0.63) | 3.14 | 0.002 | 58.5 | 0.090 | Random effect | |
| HER2 (positive vs negative) | 3 | 319 | 1.91 (0.62–5.91) | 1.12 | 0.263 | 75.8 | 0.016 | Random effect | |